HOME >> BIOLOGY >> NEWS
William C. Aird, MD, receives Established Investigator Award from American Heart Association

BOSTON William C. Aird, MD, Associate Director of the Vascular Biology Research Center at Beth Israel Deaconess Medical Center (BIDMC), has been named the recipient of a 2005 Established Investigator Award from the National Research Committee of the American Heart Association (AHA).

One of only 25 scientists to receive the AHA's prestigious award, which consists of a five-year $500,000 grant, Aird specializes in investigating endothelial cell heterogeneity, widely believed to play a critical role in both homeostasis and vascular disease states. Aird's laboratory will use the award in their continued investigations of the mechanisms that underlie differential gene expression within the endothelium and to gain a better understanding of how the endothelial cells lining the body's blood vessels are differentially regulated in space and time.

"Bill Aird's work has greatly advanced our thinking about the critical role of the endothelium to health and disease states," notes Jeffrey S. Flier, MD, BIDMC's Chief Academic Officer. "This well-deserved honor from the AHA further serves to demonstrate the fundamental importance of this area of research within the field of medicine."

A graduate of The University of Western Ontario Medical School, Aird completed residencies at St. Michael's Hospital and Toronto General Hospital, teaching hospitals of the University of Toronto. Before joining BIDMC in 1996, he held both clinical and research fellowships in medicine at Brigham and Women's Hospital, and was a postdoctoral fellow in the Department of Biology at the Massachusetts Institute of Technology. He is an Associate Professor of Medicine at Harvard Medical School.

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a res
'"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
10-Feb-2005


Page: 1 2

Related biology news :

1. SNMTS provides $50,000 in 2007 Paul Cole, Mickey Williams Minority Student Technologist Scholarships
2. Williams College biologist explores photosynthetic apparatus
3. Beyond nature vs. nurture: Williams syndrome across cultures
4. APS research awards go to undergrads at Colorado State, Michigan State, Oberlin, Williams
5. Lawrence Platt, MD, receives the 2006 AIUM William J. Fry Memorial Lecture award
6. NSF awards support for DNA analysis instrumentation lab at Williams College
7. Society of Nuclear Medicine to offer $10,000 William L. Ashburn, M.D., Pilot Research Grant for 2006
8. William C. Rose Award lecture will focus on cytochrome P450
9. Carnegie Mellons Peter Adams receives EPA research grant
10. Philadelphia ecologist receives top Mongolia honor
11. VIB scientist receives major research grant

Post Your Comments:
(Date:10/30/2014)... therapeutics present unique challenges when it comes to ... harm. New consensus guidelines for toxicity testing that ... characteristics of these novel biopharmaceuticals are presented in ... from Mary Ann Liebert, Inc. publishers . ... Nucleic Acid Therapeutics website until November 30, ...
(Date:10/30/2014)... Oct. 29, 2014  Securus Technologies, a ... technology solutions for public safety, investigation, corrections ... deployed exciting enhancements to its THREADS™ product, ... provide actionable intelligence and focused leads for ... drive technological innovation through identifying and delivering ...
(Date:10/29/2014)... Beaverton, OR) New research presented at the ... in Houston, TX showed for the first time ... in women using a readily available nutritional supplement, ... by Dr. Judith A. Smith, Pharm.D., associate professor ... Sciences at The University of Texas Health Science ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. ... will hold a conference call and live audio webcast ... to discuss its third quarter 2014 financial results. ... call by dialing (888) 347-1165 for domestic callers or ... be webcast live under the investor relations section of ...
(Date:10/30/2014)... (Oct. 29, 2014) – The severe flooding that devastated ... been less destructive if the bridges, roads and other ... new study from the University of Colorado Denver. , ... infrastructure," said Jimmy Kim, PhD, associate professor of structural ... Applied Science and lead author the study. "There is ...
(Date:10/27/2014)... October 27, 2014 The new ... Type (High & Medium), Sub-type (Primary & Secondary), ... Infrastructure & Transportation & Power Generation) - Trends ... GIS market with analysis and forecasting of the ... Data Tables with 52 Figures spread through 146 ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... (OTCQB: GNBT) today announced two presentations demonstrating that ... its novel proprietary cancer immunotherapeutic AE37 vaccine correlated ... patients. The AE37 cancer vaccine is being developed ... ( www.antigenexpress.com ). The presentations are being made ...
Breaking Biology Technology:Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
Cached News: